TLDR
- SELLAS nears Phase 3 REGAL milestone with GPS in AML patients
- SLS009 shows strong response rates in high-risk AML subtypes
- SELLAS expands clinical trials into earlier AML treatment stages
- A strong cash position supports pipeline growth and execution
- European collaboration boosts SLS009 development in AML
SELLAS Life Science (SLS) shares traded at $5.20 as it reported 2025 results and pipeline progress. The company highlighted key clinical milestones and a stronger financial position. It continues advancing therapies for acute myeloid leukaemia and other cancers.
SELLAS Life Sciences Group, Inc., SLS
The company focuses on late-stage programs targeting high-risk tumour indications. It aims to deliver new treatment options through immunotherapy and targeted approaches. Its pipeline development reflects ongoing clinical execution and strategic expansion.
GPS Program Advances Toward Phase 3 Milestone
SELLAS continues to progress with its lead candidate, GPS, in acute myeloid leukaemia. The Phase 3 REGAL trial approaches a key event-driven milestone. The study evaluates patients who achieved remission after second-line treatment.
The trial recorded 72 events by late December 2025, and it remains blinded. The company will proceed with analysis after reaching the 80th event threshold. This step will trigger database lock and topline data release.
GPS targets the WT1 protein expressed across multiple tumour types. The therapy could support both standalone and combination treatment strategies. Positive results may strengthen its role in AML immunotherapy.
SLS009 Expands Across Clinical and Preclinical Programs
SELLAS continues advancing SLS009 across several clinical stages in AML. The drug showed meaningful activity in relapsed or refractory AML patients. It achieved a 46 percent overall response rate in evaluated patients.
Patients with high-risk mutations also responded well to treatment combinations. The therapy demonstrated a favourable safety profile, with no major treatment-related complications. These findings support continued development across broader patient groups.
The company has now expanded SLS009 into earlier treatment settings. It dosed the first patient in a study involving newly diagnosed AML cases. This move aligns with efforts to address disease progression earlier.
Preclinical data also supports SLS009’s mechanism of action in cancer cells. The therapy reduces key survival proteins and promotes apoptosis. Combination use with existing drugs showed improved outcomes in models.
Financial Strength and Strategic Expansion Support Growth
SELLAS improved its financial position through warrant exercises during 2025. It raised over $67 million in gross proceeds during the year. Additional proceeds of $42.6 million followed in early 2026.
The company reported $71.8 million in cash and equivalents at year-end. These funds support ongoing clinical trials and operational activities. The strengthened balance sheet provides flexibility for pipeline execution.
Research and development expenses declined due to completed trial enrolment. General and administrative costs remained stable during the year. Net loss narrowed compared to the previous year.
SELLAS also expanded its clinical footprint through a European collaboration. The agreement supports new studies combining SLS009 with standard AML therapies. Patient enrolment for this program is expected to begin in 2026.
The company continues aligning its strategy with clinical progress and funding strength. Its programs target both advanced and early-stage treatment settings. This approach positions SELLAS for continued momentum in oncology development.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
